Table 1 Patient and disease characteristics

Age

TNM7

 Median (IQR)

61 (49–73)

IA

2,634 (41.1%)

Sex

IB

1,914 (29.8%)

 Female

3,097 (48.3%)

Stage I total

4,548

 Male

3,317 (51.7%)

IIA

529 (8.3%)

Breslow Thickness (mm)

IIB

405 (6.3%)

 Median (IQR)

0.8 (0.5–2.0)

IIC

280 (4.4%)

 0 to < 0.8

2,887 (45.0%)

Stage II total

1,214

 0.8 to 1

803 (12.5%)

IIIA

172 (2.7%)

  > 1 to 2

1,153 (18.0%)

IIIB

219 (3.4%)

  > 2 to 4

786 (12.3%)

IIIC

207 (3.2%)

  > 4

732 (11.4%)

IIID

-

 Missing

53 (0.8%)

Stage III total

598

Location

IV

54 (0.8%)

 Arm or shoulder

1,611 (25.1%)

TNM8

 Head and neck

1,168 (18.2%)

IA

3,692 (57.6%)

 Leg or hip

1,470 (22.9%)

IB

864 (13.5%)

 Trunk

2,128 (33.2%)

Stage I total

4,556

 Other, or missing

37 (0.6%)

IIA

524 (8.2%)

Ulceration

IIB

402 (6.3%)

 Present

1,080 (16.8%)

IIC

280 (4.4%)

 Absent

4,899 (76.4%)

Stage II total

1,206

 Missing

435 (6.8%)

IIIA

112 (1.8%)

Histological Subtype

IIIB

122 (1.9%)

 Melanoma, NOS

2,041 (31.8%)

IIIC

325 (5.1%)

 Nodular melanoma

781 (12.2%)

IIID

39 (0.6%)

 Lentigo maligna melanoma

441 (6.9%)

Stage III total

598

 Superficial spreading melanoma

2,684 (41.9%)

IV

54 (0.8%)

 Acral lentiginous melanoma

98 (1.5%)

T category

 Other

369 (5.8%)

TNM7

Mitotic rate (per mm²)

T1a

2,653 (41.4%)

  < 1

1,785 (27.8%)

T1b

1,053 (16.4%)

  ≥ 1

3,150 (49.1%)

T2a

992 (15.5%)

 Missing

1,479 (23.1%)

T2b

186 (2.9%)

Residential Area

T3a

459 (7.2%)

 Urban (RIO < 10)

3,862 (60.2%)

T3b

338 (5.3%)

 Suburban (10 ≤ RIO < 40)

1,809 (28.2%)

T4a

242 (3.8%)

 Rural (RIO ≥ 40)

677 (10.6%)

T4b

491 (7.7%)

 Missing

66 (1.0%)

TNM8

Neighbourhood income quintile

T1a

2,910 (45.4%)

 1 (Lowest)

879 (13.7%)

T1b

833 (13.0%)

 2

1,079 (16.8%)

T2a

967 (15.1%)

 3

1,248 (19.5%)

T2b

186 (2.9%)

 4

1,442 (22.5%)

T3a

452 (7.1%)

 5 (Highest)

1,749 (27.3%)

T3b

334 (5.2%)

 Missing

17 (0.3%)

T4a

241 (3.8%)

Elixhauser comorbidity index

T4b

491 (7.7%)

 Mean ± SD

0.3 ± 0.9

N category

  0

5,347 (83.4%)

TNM7

  1

558 (8.7%)

Nx

5,351 (83.4%)

  2–3

362 (5.6%)

N0

441 (6.9%)

  4 + 

147 (2.3%)

N1a

224 (3.5%)

Adjuvant/palliative systemic therapy

N1b

37 (0.6%)

 Any systemic therapy

413 (6.4%)

N2a

105 (1.6%)

Adjuvant systemic therapy

N2b

22 (0.3%)

 Interferon

372 (5.8%)

N2c

119 (1.9%)

Palliative systemic therapy

N3

115 (1.8%)

 Any systemic therapy

51 (0.8%)

TNM8

 Dacarbazine

26 (0.4%)

Nx

5,351 (83.4%)

 Carbo-Taxol

8 (0.1%)

N0

441 (6.9%)

 Temozolomide

 ≤ 5 (≤ 0.1%)

N1a

224 (3.5%)

 BRAF and/or MEK

12 (0.2%)

N1b

37 (0.6%)

 Immunotherapy

 ≤ 5 (≤ 0.1%)

N1c

119 (1.9%)

Adjuvant/palliative radiotherapy

N2a

105 (1.6%)

 Any body site

196 (3.1%)

N2b

22 (0.3%)

 Brain-directed treatment

37 (0.6%)

N2c

30 (0.5%)

 Non-brain-directed treatment

181 (2.8%)

N3a

16 (0.3%)

N3b

26 (0.4%)

N3c

43 (0.7%)